Medical Condition News

RSS

Biomoda joins Saccomanno Research Institute to advance CyPath technology for cancer detection

Cancer diagnostics company Biomoda, Inc. is working with the Saccomanno Research Institute to advance Biomoda's patented system for measuring the photon emission rate of CyPath-stained cells to detect early-stage lung cancer.

8 Sep 2010

Yeast can be simple model to study molecular basis of Parkinson’s disease

Yeast could be a powerful ally in the discovery of new therapeutic drugs to treat Parkinson's disease says a scientist presenting his work at the Society for General Microbiology's autumn meeting in Nottingham today.

8 Sep 2010

AHRQ releases free evidence-based guides for eight health conditions

HHS' Agency for Healthcare Research and Quality today released a series of free evidence-based guides designed to help Spanish speakers understand and compare the risks, benefits and side effects of treatments for eight health conditions.

7 Sep 2010

Schizophrenia linked to lack of Vitamin D: study

Researchers at Queensland Brain Institute have found that babies born with low vitamin D levels are twice as likely to develop schizophrenia later in life. This could mean that it may be possible to prevent schizophrenia, which affects almost 200,000 Australians.

7 Sep 2010

Short sleep duration associated with elevated risk of diabetes, heart disease and stroke

People who sleep less than six hours a night may be three times more likely to develop a condition which leads to diabetes and heart disease, according to researchers at the University of Warwick.

7 Sep 2010

Methylphenidate facilitates recovery from drug addiction

A brain-scanning study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, conducted with collaborators from Stony Brook University, reveals that an oral dose of methylphenidate, commonly known as Ritalin, improves impaired brain function and enhances cognitive performance in people who are addicted to cocaine.

7 Sep 2010

Medtronic launches CoreValve delivery system with AccuTrak Stability Layer for TAVI

Medtronic, Inc. today announced CE Mark approval and the first global use and launch of the Medtronic CoreValve® delivery system with AccuTrak™ Stability Layer for transcatheter aortic valve implantation (TAVI). AccuTrak's proprietary technology allows physicians to achieve enhanced control and accuracy in the deployment of the CoreValve device.

7 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

K2M granted FDA clearance for CHESAPEAKE Anterior-Lumbar Stabilization System

K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.

7 Sep 2010

Somaxon's Silenor now commercially available in U.S.

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that Silenor® (doxepin) now is commercially available by prescription in the United States. Somaxon has implemented a wholesale and retail stocking program to disseminate Silenor 3 mg and 6 mg dosepacks to pharmacies across the United States. Silenor is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

7 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.

7 Sep 2010

TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma

TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients (ClinicalTrials.gov identifier: NCT00127881). The trial enrollment was suspended in October 2008 while Genmab was seeking a out-license agreement to further develop the compound. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from Genmab.

7 Sep 2010

GI Dynamics announces data on EndoBarrier therapy for type 2 diabetes, obesity

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced data with the EndoBarrier Gastrointestinal Liner at 12 months showing significant weight loss and cardiovascular and metabolic improvements in obese patients.

7 Sep 2010

RA synthetic derivative 4-HPR's ability to induce tumour cell death

Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25 % of cases and which can lead to death. The development of 4-HPR, a synthetic derivative of RA, has meant a considerable advance due to its greater efficacy compared to its predecessor.

7 Sep 2010

NHS Choices unveils typical signs, symptoms of cancer

More than 1/3 people in the UK will develop some form of cancer during their lifetime.The good news is that some cancers can be cured if detected early enough. The key is to be aware of unexplained changes to your body, and to know the common signs and symptoms of cancer.

7 Sep 2010

Medtronic announces international launch of Resolute Integrity Stent System

Medtronic, Inc. (NYSE: MDT), announces the CE (Conformite Europeene) mark and international launch of the Resolute Integrity Stent System for the treatment of coronary artery disease, a leading cause of death and poor quality of life.

7 Sep 2010

Risk of late onset TRAS in living unrelated donor kidney recipients

Patients who have received a new kidney are significantly more likely to develop transplant renal artery stenosis (TRAS) if they are obese or over 50, according to research published in the September issue of the Journal of Renal Care.

7 Sep 2010

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood, according to a report published online today that will appear in the January 2011 print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

7 Sep 2010

Research suggests blocking HMGB1 protein can benefit cancer patients

Like some people, cells eat when they are under pressure-but they consume parts of themselves. A multi-function protein helps control this form of cannibalism, according to a study in the September 6 issue of the Journal of Cell Biology.

7 Sep 2010

Medical Condition News

Biomoda joins Saccomanno Research Institute to advance CyPath technology for cancer detection

Yeast can be simple model to study molecular basis of Parkinson’s disease

AHRQ releases free evidence-based guides for eight health conditions

Schizophrenia linked to lack of Vitamin D: study

Short sleep duration associated with elevated risk of diabetes, heart disease and stroke

Methylphenidate facilitates recovery from drug addiction

Medtronic launches CoreValve delivery system with AccuTrak Stability Layer for TAVI

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

K2M granted FDA clearance for CHESAPEAKE Anterior-Lumbar Stabilization System

Somaxon's Silenor now commercially available in U.S.

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma

GI Dynamics announces data on EndoBarrier therapy for type 2 diabetes, obesity

RA synthetic derivative 4-HPR's ability to induce tumour cell death

NHS Choices unveils typical signs, symptoms of cancer

Medtronic announces international launch of Resolute Integrity Stent System

Risk of late onset TRAS in living unrelated donor kidney recipients

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

Research suggests blocking HMGB1 protein can benefit cancer patients

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News